GRITSTONE BIO, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.805 USD | +0.42% |
|
-2.31% | -60.28% |
| May. 24 | B. Riley Cuts Price Target on Gritstone bio to $3 From $6, Keeps Buy Rating | MT |
| May. 09 | Earnings Flash (GRTS) GRITSTONE BIO Posts Q1 Revenue $1.74M, vs. Street Est of $2.85M | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- The company's enterprise value to sales, at 6.15 times its current sales, is high.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -60.28% | 87.03M | D+ | ||
| -1.64% | 90.28B | A- | ||
| -1.84% | 39.5B | A- | ||
| -16.07% | 31.71B | B- | ||
| +61.03% | 26.41B | A | ||
| -22.13% | 14.34B | C | ||
| -9.22% | 12.89B | B- | ||
| -10.32% | 11.8B | D+ | ||
| -45.77% | 10.95B | B | ||
| +3.00% | 8.85B | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- GRTS Stock
- Ratings Gritstone bio, Inc.
